Menu
PacPremier
Magic Hour
Montecito
Loading...
You are here:  Home  >  'Neupogen'
Latest

Amgen buying out joint venture Kirin-Amgen for $780 million

By   /  Tuesday, October 31st, 2017  /  Central Coast Health Watch, Latest news, Technology  /  Comments Off on Amgen buying out joint venture Kirin-Amgen for $780 million

Amgen, the biotech giant based in Thousand Oaks, announced that it would buy out joint venture Kirin-Amgen, which was created to develop white blood cell booster Neupogen among other projects, for $780 million. The joint venture holds intellectual property rights for Neupogen, Neulasta, Aranesp, Nplate and brodalumab. In addition to the cash deal, Amgen will Read More →

Read More →
Latest

CVS Health will not cover Amgen’s Neupogen in favor of Novartis biosimilar

By   /  Thursday, August 4th, 2016  /  Central Coast Health Watch, Latest news  /  Comments Off on CVS Health will not cover Amgen’s Neupogen in favor of Novartis biosimilar

CVS Health will no longer cover Thousand Oaks-based Amgen’s Neupogen on its standard drug plan in 2017, favoring the biosimilar Zarxio from Novartis. CVS, which is the second largest benefits manager behind Express Scripts and also owns the largest chain of drug stores in the U.S., said Aug. 2 it will choose biosimilar drugs over Read More →

Read More →
Latest

Thousand Oaks’ Amgen just keeps chugging along

By   /  Friday, February 5th, 2016  /  Central Coast Health Watch, Earnings, East Ventura County, middle, Tri-County Public Companies  /  Comments Off on Thousand Oaks’ Amgen just keeps chugging along

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen revenues up 8 percent in 2015

By   /  Thursday, January 28th, 2016  /  Central Coast Health Watch, Earnings, East Ventura County, Latest news, Top Stories, Tri-County Public Companies  /  Comments Off on Amgen revenues up 8 percent in 2015

Despite increased competition from biosimilars and blockbuster mergers by its rivals, Amgen revenues rose 8 percent to $21.67 billion in 2015 from $20.06 billion in 2014. Thousand Oaks-based biotech giant Amgen released its fourth-quarter earnings after markets closed on Jan. 28. Quarterly revenues were also up 4 percent to $5.54 billion in 2015 from $5.33 Read More →

Read More →
Latest

Amgen shares drop as Novartis launches cheaper drug

By   /  Thursday, September 3rd, 2015  /  Central Coast Health Watch, East Ventura County, Latest news, Top Stories, Tri-County Public Companies  /  Comments Off on Amgen shares drop as Novartis launches cheaper drug

Amgen, the giant biotech company based in Thousand Oaks, saw its shares drop 2 percent to $149.23 on Sept. 3 after its rival Novartis launched a drug similar to Amgen’s that costs 15 percent less. Novartis’ Zarxio and Amgen’s Neupogen both help chemotherapy patients battle infections by increasing the production of white blood cells. The Read More →

Read More →